Why did GNCA stock drop so sharply pre-market?

GNCA stock fell on thin liquidity and lingering Chapter 11 restructuring concerns. Sparse corporate updates and low trading interest amplified the drop to **$0.0001**.

What is the Meyka AI grade and recommendation for GNCA stock?

Meyka AI rates GNCA **58.75 / 100**, Grade **C+**, Suggestion **HOLD**. The grade balances modest assets against high restructuring and liquidity risk.

What is the near-term forecast for GNCA stock?

Meyka AI's forecast model projects **$0.0001** for GNCA stock, implying **0.00%** near-term change. Forecasts are projections and not guarantees. Monitor restructuring updates.

Does Genocea have meaningful cash or assets per share?

Trailing metrics show **cash per share $0.54** and book value per share **$0.39**. These figures suggest some asset backing but do not ensure equity recovery.

US Stocks

GNCA (Genocea Biosciences) NASDAQ down 97.44% to $0.0001 pre-market 13 Jan 2026: See liquidity

ByDanny Kontos January 13, 2026January 13, 2026

GNCA stock opened the pre-market session on 13 Jan 2026 at $0.0001, down 97.44% from the previous close. This dramatic move places Genocea Biosciences, Inc. (GNCA) among the top pre-market losers on NASDAQ in the United States. Volume was modest at 30,268.00 shares versus a 50‑day average near 80,568.00. The immediate drivers include long-running Chapter 11 restructuring, scarce liquidity, and weak trading interest. We examine valuation, cash metrics, the Meyka AI grade, and a short-form forecast for GNCA stock to help traders prioritize next steps.